Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

Frontiers in Pediatrics - Switzerland
doi 10.3389/fped.2020.00048
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

X-Linked Hypophosphatemia: New Horizons

Clinical Pediatric Endocrinology
Child HealthEndocrinologyPerinatologyPediatricsMetabolismDiabetes
2005English

Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia

Journal of Bone and Mineral Research
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2018English

One-Year Metreleptin Improves Insulin Secretion in Patients With Diabetes Linked to Genetic Lipodystrophic Syndromes

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

HLA-Cw6-positive Patients With Psoriasis Show Improved Response to Methotrexate Treatment

Clinical and Experimental Dermatology
Dermatology
2017English

Antinuclear Antibodies Are Common and Linked to Poor Response to Omalizumab Treatment in Patients With CSU

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Hypertension Is a Characteristic Complication of X-Linked Hypophosphatemia

Endocrine Journal
EndocrinologyMetabolismDiabetes
2017English

One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2014English

One-Year Mortality in Patients With Community-Acquired Pneumonia

Journal of Respiratory Infections
2017English

Aberrant Phex Function in Osteoblasts and Osteocytes Alone Underlies Murine X-Linked Hypophosphatemia

Journal of Clinical Investigation
Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy